Johnson & Johnson

NYSE:JNJ   3:59:59 PM EDT
169.95
+1.75 (+1.04%)
4:57:33 PM EDT: $170.04 +0.09 (+0.05%)
Earnings Announcements

Health Canada Approves Tremfya (Guselkumab Injection), A First-In-Class Selective Interleukin (Il)-23 Inhibitor For Active Psoriatic Arthritis

Published: 09/10/2020 13:01 GMT
Johnson & Johnson (JNJ) - Health Canada Approves Tremfya (guselkumab Injection), a First-in-class Selective Interleukin (il)-23 Inhibitor for Active Psoriatic Arthritis.
Revenue is expected to be $22.52 Billion
Adjusted EPS is expected to be $2.29

Next Quarter Revenue Guidance is expected to be $23.45 Billion
Next Quarter EPS Guidance is expected to be $2.40

More details on our Analysts Page.